このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Intra-Cellular Therapies 将来の成長

Future 基準チェック /56

Intra-Cellular Therapies利益と収益がそれぞれ年間59.8%と29.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に25.8% 59.7%なると予測されています。

主要情報

63.2%

収益成長率

62.5%

EPS成長率

Pharmaceuticals 収益成長	22.6%
収益成長率	32.4%
将来の株主資本利益率	11.9%
アナリストカバレッジ	Good
最終更新日	08 Aug 2024

今後の成長に関する最新情報

Recent updates

With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Jul 27

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Mar 17

Intra-Cellular Therapies Is On Fire

Mar 11

Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'

Feb 11

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

Dec 24

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Nov 11

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Aug 07

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

May 09

After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

Apr 17

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Jan 31

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Oct 25

Intra-Cellular Therapies: What Lies Ahead

Sep 20

Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug

Aug 22

Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M

Aug 09

We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Jul 09

Intra-Cellular Therapies: A Dramatic Story

Jun 18

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Apr 03

Intra-Cellular: Not Participating In A Bear Market

Mar 31

Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand

Mar 08

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Dec 24

Intra-Cellular's Second FDA Win Makes It A Great Long-Term Investment

Dec 21

業績と収益の成長予測

NasdaqGS:ITCI - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,354	474	547	497	14
12/31/2025	917	118	187	126	15
12/31/2024	668	-67	-41	4	12
6/30/2024	565	-84	-61	-61	N/A
3/31/2024	514	-111	-99	-98	N/A
12/31/2023	464	-140	-124	-124	N/A
9/30/2023	420	-155	-162	-161	N/A
6/30/2023	366	-184	-190	-189	N/A
3/31/2023	311	-228	-248	-247	N/A
12/31/2022	250	-256	-271	-270	N/A
9/30/2022	188	-298	-305	-304	N/A
6/30/2022	138	-321	-331	-330	N/A
3/31/2022	103	-304	-296	-295	N/A
12/31/2021	84	-284	-260	-260	N/A
9/30/2021	71	-259	-255	-255	N/A
6/30/2021	56	-237	-239	-239	N/A
3/31/2021	38	-232	-227	-227	N/A
12/31/2020	23	-227	-230	-230	N/A
9/30/2020	10	-207	-196	-197	N/A
6/30/2020	3	-187	-163	-163	N/A
3/31/2020	1	-160	-144	-144	N/A
12/31/2019	0	-148	-129	-128	N/A
9/30/2019	N/A	-148	-123	-122	N/A
6/30/2019	N/A	-155	-122	-121	N/A
3/31/2019	N/A	-154	-127	-127	N/A
12/31/2018	N/A	-155	-119	-118	N/A
9/30/2018	0	-145	-115	-114	N/A
6/30/2018	0	-126	-101	-100	N/A
3/31/2018	0	-106	N/A	-91	N/A
12/31/2017	0	-98	N/A	-80	N/A
9/30/2017	0	-95	N/A	-84	N/A
6/30/2017	0	-102	N/A	-99	N/A
3/31/2017	0	-116	N/A	-88	N/A
12/31/2016	0	-116	N/A	-91	N/A
9/30/2016	0	-118	N/A	-98	N/A
6/30/2016	0	-120	N/A	-89	N/A
3/31/2016	0	-110	N/A	-106	N/A
12/31/2015	0	-105	N/A	-102	N/A
9/30/2015	0	-91	N/A	-73	N/A
6/30/2015	0	-65	N/A	-57	N/A
3/31/2015	0	-48	N/A	-32	N/A
12/31/2014	1	-31	N/A	-23	N/A
9/30/2014	1	-24	N/A	-25	N/A
6/30/2014	2	-22	N/A	-26	N/A
3/31/2014	2	-26	N/A	-27	N/A
12/31/2013	3	-27	N/A	-23	N/A
9/30/2013	3	-20	N/A	-18	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ITCIは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: ITCI今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: ITCI今後 3 年以内に収益を上げることが予想されます。

収益対市場: ITCIの収益 ( 29.8% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: ITCIの収益 ( 29.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ITCIの自己資本利益率は、3年後には低くなると予測されています ( 11.9 %)。

Intra-Cellular Therapies 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Intra-Cellular Therapies, Inc. Raises Sales Guidance for 2024

Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Full Year 2024

Price target increased by 8.3% to US$89.93

Consensus EPS estimates fall by 28%

Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2024

Intra-Cellular Therapies, Inc. Provides Sales Guidance for the Fiscal Year 2023

Recent updates

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Intra-Cellular Therapies, Inc. Raises Sales Guidance for 2024

With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from Russell 2000 Dynamic Index

Lead Independent Director notifies of intention to sell stock

Intra-Cellular Brightens MDD Outlook With Caplyta Success

Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Intra-Cellular Therapies, Inc., Annual General Meeting, Jun 14, 2024

Price target increased by 8.3% to US$89.93

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $500.000068 million.

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $500.000068 million.

New minor risk - Shareholder dilution

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

Intra-Cellular Therapies, Inc. Announces Retirement of Larry Hineline as Chief Financial Officer

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Intra-Cellular Therapies Is On Fire

Co-Founder notifies of intention to sell stock

Consensus EPS estimates fall by 28%

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS exceeds analyst expectations

Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2024

Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'

Co-Founder notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

Executive VP & Chief Medical Officer notifies of intention to sell stock

Executive VP notifies of intention to sell stock

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

EVP & Chief Commercial Officer recently sold US$860k worth of stock

EVP & Chief Commercial Officer notifies of intention to sell stock

Intra-Cellular Therapies, Inc. Provides Sales Guidance for the Fiscal Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Co-Founder notifies of intention to sell stock

EVP & Chief Commercial Officer notifies of intention to sell stock

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Senior VP of Finance notifies of intention to sell stock

Intra-Cellular Therapies, Inc. Announces CAPLYTA Data Presentations At the American Society of Clinical Psychopharmacology Annual Meeting

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lead Independent Director exercised options and sold US$500k worth of stock

After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

Co-Founder exercised options and sold US$925k worth of stock

Consensus EPS estimates fall by 33%

Full year 2022 earnings: EPS exceeds analyst expectations

Senior VP of Finance exercised options and sold US$2.5m worth of stock

Forecast breakeven date pushed back to 2025

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Forecast breakeven date pushed back to 2025

Independent Director recently sold US$254k worth of stock

Executive VP exercised options and sold US$1.9m worth of stock

Independent Director recently sold US$523k worth of stock

Independent Director recently sold US$523k worth of stock

Consensus estimates of losses per share improve by 12%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Senior VP of Finance exercised options and sold US$2.0m worth of stock

Intra-Cellular Therapies: What Lies Ahead

Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug

Independent Director recently sold US$592k worth of stock

Lead Independent Director exercised options and sold US$1.3m worth of stock